We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+11.03%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$10.6B
AUM Growth
+$1.17B
(+12%)
Cap. Flow
+$3.01B
Cap. Flow
% of AUM
28.27%
Top 10 Holdings %
Top 10 Hldgs %
22.3%
Holding
850
New
52
Increased
273
Reduced
342
Closed
48
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$96.9M |
| 2 |
Merck
MRK
|
+$73.5M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$57.1M |
| 4 |
Illumina
ILMN
|
+$40.4M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$34.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$57.2M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$51.7M |
| 3 |
Kimberly-Clark
KMB
|
+$28.5M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$26.5M |
| 5 |
Arista Networks
ANET
|
+$22.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.77% |
| 2 | Technology | 20.35% |
| 3 | Consumer Discretionary | 9.49% |
| 4 | Communication Services | 7.69% |
| 5 | Financials | 7.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Tyler Technologies
TYL
$13.3B
| $909K | 0.01% |
2,608
+67
| +3% | +$23.2K |
|
602
Gildan
GIL
$9.72B
| $907K | 0.01% |
46,197
-5,607
| -11% | -$104K |
|
|
DISCK
603
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $901K | 0.01% |
45,954
| – | – |
|
604
ONE Gas
OGS
$4.9B
| $884K | 0.01% |
12,810
-120
| -0.9% | -$8.84K |
|
605
Teledyne Technologies
TDY
$30.1B
| $879K | 0.01% |
2,834
| – | – |
|
606
Canadian Imperial Bank of Commerce
CM
$108B
| $877K | 0.01% |
23,550
-200
| -0.8% | -$7.32K |
|
607
Las Vegas Sands
LVS
$32.3B
| $876K | 0.01% |
18,785
+1,000
| +6% | +$47.8K |
|
608
Genuine Parts
GPC
$17.2B
| $873K | 0.01% |
9,172
| – | – |
|
609
NVR
NVR
$16.8B
| $866K | 0.01% |
212
+7
| +3% | +$27K |
|
610
Dentsply Sirona
XRAY
$2.75B
| $862K | 0.01% |
19,715
| – | – |
|
611
MGM Resorts International
MGM
$11.7B
| $858K | 0.01% |
39,429
-2,488
| -6% | -$49.3K |
|
612
Assurant
AIZ
$14B
| $845K | 0.01% |
6,966
| – | – |
|
|
RDHL
613
Redhill Biopharma
RDHL
$3.84M
| $843K | 0.01% |
83
| – | – |
|
614
Bunge Global
BG
$20.4B
| $832K | 0.01% |
18,201
| – | – |
|
615
Insulet
PODD
$11.5B
| $828K | 0.01% |
+3,498
| New | +$737K |
|
616
iShares MSCI China ETF
MCHI
$6.28B
| $816K | 0.01% |
11,000
-5,000
| -31% | -$366K |
|
617
Liberty Broadband Class C
LBRDK
$4.79B
| $806K | 0.01% |
5,645
-886
| -14% | -$122K |
|
618
Fox Class B
FOX
$22B
| $804K | 0.01% |
28,735
| – | – |
|
|
CTLT
619
DELISTED
CATALENT, INC.
CTLT
| $800K | 0.01% |
9,344
| – | – |
|
|
PBCT
620
DELISTED
People's United Financial Inc
PBCT
| $799K | 0.01% |
77,477
-2,993
| -4% | -$32.5K |
|
621
Ingersoll Rand
IR
$33B
| $797K | 0.01% |
22,401
-3,656
| -14% | -$122K |
|
622
Mid-America Apartment Communities
MAA
$15.5B
| $797K | 0.01% |
6,870
-637
| -8% | -$73.4K |
|
623
Annaly Capital Management
NLY
$17.3B
| $797K | 0.01% |
27,994
-834
| -3% | -$24.1K |
|
|
SIVB
624
DELISTED
SVB Financial Group
SIVB
| $773K | 0.01% |
3,214
+41
| +1% | +$9.64K |
|
625
NetApp
NTAP
$34.1B
| $771K | 0.01% |
17,590
-2,000
| -10% | -$87.3K |
|
Similar funds
PCM
A
MGP
LF
BPA
MIM
SPIA
Candriam SCA's Q3 2020 Portfolio in Review
As of Q3 2020, Candriam SCA held 850 positions worth $10.6B, up 12% from $9.47B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $3.01B of net new capital in Q3 2020, opening 52 new positions and adding to 273 existing holdings. Its largest new stake was VIVINT SOLAR, INC.: 840,936 shares worth $35.6M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 35% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $57.2M trimmed.
- Candriam SCA's largest Q3 2020 buy was VIVINT SOLAR, INC.: 840,936 shares worth $35.6M.
- Candriam SCA added most to Amgen in Q3 2020, an estimated $96.9M increase.
- Candriam SCA's biggest Q3 2020 reduction was Apple, cutting an estimated $57.2M.
- Candriam SCA fully exited G1 Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $21.1M.
- Candriam SCA's ten largest holdings make up 22% of its $10.6B portfolio in Q3 2020.
- Candriam SCA opened 52 new positions and closed 48 in Q3 2020.
- Candriam SCA's portfolio value rose 12% quarter-over-quarter to $10.6B.
Based on Candriam SCA's 13F filing for Q3 2020, filed 19 Oct 2020.